EH
Elaine Hamm
No background info available
Check back soon. More details may be added later.
Partnering listings
Learn more
Ascendis Pharma
Epigenome therapy for SNCA modulation in Parkinson's Disease
A targeted epigenetic approach to downregulate SNCA expression in dopaminergic neurons, aiming to reduce α-synuclein pathology and neurodegeneration in Parkinson's Disease. This method seeks to maintain physiological SNC...
TechnologyConceptualCompany
Ascendis Pharma
Targeted APOEe4 gene therapy for Alzheimer's disease treatment
A novel gene therapy targeting APOEe4 expression aims to reduce amyloid-β pathology, decrease neuroinflammation, and slow cognitive decline in Alzheimer's patients without detrimental effects of complete APOE elimination...
TechnologyConceptualCompany
A novel gene-therapy strategy for Parkinson's disease (PD): Epigenome editing mediated-regulation of SNCA expression
Michael J. Fox Foundation for Parkinson's Research
•$500,000
•2022 - 2023
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.
delivered to your inbox.
© 2026 Halo Cures, Inc.